Search Articles

The world's largest companies, from the Dutch East India Company in the 1640s to Apple in 2024, were driven by globally distributable products. Living technology doesn't have one yet – not even obesity drugs will come close.

The DNA sequencing leader raised only $36 million in venture capital and just $96 million at its IPO. Illumina achieved its first operating profit eight years after being founded and has been cash flow positive since 2006.

One quarter through the "century of biology," we're great at building startups deemed successful by the vanity metrics of success, but terrible at building commercially successful businesses.

The founders nailed the timing for the company's public debut in 2021, but the short-term tradeoffs made then are now biting investors. A fair valuation on the other side of $1 per share leaves only one option.

Shield is likely to become the second blood test approved to screen for colon cancer, but reimbursement coverage might disappoint investors and complicate commercial launch.

The global drug development industry boasted 152 blockbuster drugs that generated combined revenue of $511 billion in 2023. Over 58% percent ($298 billion) was generated from patients in the United States.

Recent biotech winners include Solugen, Modern Meadow, and Provivi. But analysis of the program's 27-year history serves as a reminder that biology-based technology isn't the only sustainable technology around.

Artificial intelligence and machine learning help researchers to shape large datasets, but incredible computing power is still needed to muscle through biological data in a reasonable time. That's where machines such as Anton 2 and BioHive-1 come into play.

It's fun to dream big, especially when it leads to big funding rounds. Yet, few companies translate startup success into a sustainable business. We interviewed entrepreneurs throughout living tech to understand why the gap exists.

The darling of synthetic biology has sworn off manufacturing and scale-up assets, opting to build a horizontal technology platform serving all biotech sectors. The lack of vertical integration could hurt the business in the long run.

The synthetic biology pioneer has been chronically mismanaged in the decade since pivoting away from biofuels. Despite severely overpromising and underdelivering, the management team has faced almost no consequences.

A 2016 partnership between Ginkgo Bioworks and Amyris pooled together over 70 development-stage ingredients across flavor and fragrance verticals. By the end of 2022, only eight had been commercialized. What happened?

Investors often hear of the significant difficulties in ramping up industrial manufacturing processes, such as for automobiles or wind turbines. But the most challenging scale up might occur in biopharma and industrial biotech.

The genetic testing company announced the transition of its longtime CEO. It hopes to pivot and turn a corner, but investors shouldn't get their hopes up.